Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection

被引：2

作者：

Hashii, Yoshiko ^{[1
]}

Kusuki, Shigenori ^{[2
]}

Takizawa, Sachiko ^{[6
]}

Tokimasa, Sadao ^{[3
]}

Ohta, Hideaki ^{[4
]}

Hara, Junichi ^{[5
]}

Ozono, Keiichi ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Dev Med, Suita, Osaka 5650871, Japan

[2] Natl Hosp Org Osaka Natl Hosp, Dept Pediat, Osaka, Japan

[3] Osaka City Univ, Grad Sch Med, Dept Pediat, Osaka 558, Japan

[4] Higashitoyonakawatanabe Hosp, Dept Pediat, Osaka, Japan

[5] Osaka City Gen Hosp, Dept Pediat Hematol Oncol, Osaka, Japan

[6] Ikeda City Hosp, Dept Pediat, Ikeda, Osaka, Japan

来源：

PEDIATRICS INTERNATIONAL | 2014年 / 56卷 / 06期

关键词：

immunocompromised host; invasive fungal infection; micafungin; pediatric patient; CLINICAL-PRACTICE GUIDELINES; CELL TRANSPLANT RECIPIENTS; DISEASES SOCIETY; CANDIDA; SURVEILLANCE; ASPERGILLOSIS; EPIDEMIOLOGY; AMERICA;

D O I：

10.1111/ped.12356

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

BackgroundMicafungin, an antifungal echinocandin, has been indicated for pediatric patients with invasive fungal infection (IFI) in Japan and Europe. Its efficacy in immunocompromised pediatric patients with IFI, however, has not been fully investigated. MethodsThe safety and efficacy of micafungin as an antifungal therapy were analyzed in nine consecutive severe immunocompromised patients with IFI. ResultsThree patients with proven or probable Candida infections had complete response to micafungin therapy. Of the other six patients with proven, probable or possible Aspergillus infection, four had complete response and one had partial response to micafungin treatment. No severe adverse events were observed. ConclusionsIn this small series, micafungin was effective for IFI caused by both Candida and Aspergillus species and no severe adverse events were observed in these immunocompromised patients.

引用

页码：834 / 837

页数：4

共 19 条

[1] Fungal infections in children with cancer - A prospective, multicenter surveillance study
Castagnola, Elio
Cesaro, Simone
Giacchino, Mareva
Livadiotti, Susanna
Tucci, Fabio
Zanazzo, Giulio
Caselli, Desire
Caviglia, Ilaria
Parodi, Stefano
Rondelli, Roberto
Cornelli, Pier Emilo
Mura, Rossella
Santoro, Nicola
Russo, Giovanna
De Santis, Raffaella
Buffardi, Salvatore
Viscoli, Claudio
Haupt, Riccardo
Rossi, Mario R.
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (07) : 634 - 639
[2] Micafungin: A new echinocandin
Chandrasekar, PH
Sobel, JD
[J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) : 1171 - 1178
[3] Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
De Pauw, Ben
Walsh, Thomas J.
Donnelly, J. Peter
Stevens, David A.
Edwards, John E.
Calandra, Thierry
Pappas, Peter G.
Maertens, Johan
Lortholary, Olivier
Kauffman, Carol A.
Denning, David W.
Patterson, Thomas F.
Maschmeyer, Georg
Bille, Jacques
Dismukes, William E.
Herbrecht, Raoul
Hope, William W.
Kibbler, Christopher C.
Kullberg, Bart Jan
Marr, Kieren A.
Munoz, Patricia
Odds, Frank C.
Perfect, John R.
Restrepo, Angela
Ruhnke, Markus
Segal, Brahm H.
Sobel, Jack D.
Sorrell, Tania C.
Viscoli, Claudio
Wingard, John R.
Zaoutis, Theoklis
Bennett, John E.
[J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) : 1813 - 1821
[4] Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
Denning, David W.
Marr, Kieren A.
Lau, Wendi M.
Facklam, David P.
Ratanatharathorn, Voravit
Becker, Cornelia
Ullmann, Andrew J.
Seibel, Nita L.
Flynn, Patricia M.
van Burik, Jo-Anne H.
Buell, Donald N.
Patterson, Thomas F.
[J]. JOURNAL OF INFECTION, 2006, 53 (05) : 337 - 349
[5] Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections
Ikawa, Kazuro
Nomura, Kenichi
Morikawa, Norifumi
Ikeda, Kayo
Taniwaki, Masafumi
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) : 840 - 844
[6] Role of micafungin in the antifungal armamentarium
Ikeda, Fumiaki
Tanaka, Shigeki
Ohki, Hidenori
Matsumoto, Satoru
Maki, Katsuyuki
Katashima, Masataka
Barrett, David
Aoki, Yoshiyasu
[J]. CURRENT MEDICINAL CHEMISTRY, 2007, 14 (11) : 1263 - 1275
[7] Kai M, 2006, JPN J PEDIAT HEMATOL, V20, P45
[8] Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis
Kontoyiannis, D. P.
Ratanatharathorn, V.
Young, J. -A.
Raymond, J.
Laverdiere, M.
Denning, D. W.
Patterson, T. F.
Facklam, D.
Kovanda, L.
Arnold, L.
Lau, W.
Buell, D.
Marr, K. A.
[J]. TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (01) : 89 - 93
[9] Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients
Marr, KA
Carter, RA
Crippa, F
Wald, A
Corey, L
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (07) : 909 - 917
[10] Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer, SA
Diekema, DJ
Boyken, L
Tendolkar, S
Hollis, RJ
Pfaller, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (02) : 324 - 326

← 1 2 →